Calcimimetics Adherence and Preference in the Management of Uremic Secondary Hyperparathyroidism (SHPT) in Europe

被引：0

作者：

Nduka, Chidozie U. ^{[1
]}

Louie, Karly S. ^{[1
]}

Taylor, Jo ^{[2
]}

Hall, Matt ^{[3
]}

Aucella, Filippo ^{[4
]}

Torres, Pablo A. Urena ^{[5
,6
]}

Labriola, Laura ^{[7
]}

Evenepoel, Pieter ^{[8
]}

Ma, Junjie ^{[12
]}

Saleem, Najma ^{[12
]}

Pisoni, Ronald L. ^{[9
]}

Fouqueray, Bruno L. ^{[10
]}

Horne, Robert ^{[11
]}

机构：

[1] Amgen Inc, Uxbridge, Middx, England

[2] Dorset Cty Hosp NHS Fdn Trust, Dorchester, England

[3] Nottingham Univ Hosp NHS Trust, Nottingham, England

[4] Fdn IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy

[5] AURA Paris Nord, St Ouen, France

[6] Univ Paris 05, Necker Hosp, Paris, France

[7] Catholic Univ Louvain, Clin Univ St Luc, Dept Nephrol, Brussels, Belgium

[8] Univ Hosp Leuven, Div Nephrol, Dept Immunol & Microbiol, Leuven, Belgium

[9] Arbor Res Collaborat Hlth, Ann Arbor, MI USA

[10] Amgen GmbH, Rotkreuz, Switzerland

[11] UCL, Sch Pharm, London, England

[12] Amgen Inc, Thousand Oaks, CA USA

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

SA-PO325

引用

页码：694 / 694

页数：1

共 50 条

[41] Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients
Akizawa, T
Suzuki, M
Akiba, T
Nishizawa, Y
Kurokawa, K
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S147 - S151
[42] Race is a major determinant of secondary hyperparathyroidism in uremic patients
Gupta, A
Kallenbach, LR
Zasuwa, G
Divine, GW
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2000, 11 (02): : 330 - 334
[43] Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients
Regidor, M. J. Aladren
CLINICAL NEPHROLOGY, 2009, 71 (02) : 297 - 213
[44] Paricalcitol(Zemplar®) capsule controls secondary hyperparathyroidism (SHPT) in CKD stage 5 patients
Qiu, P
Gonzalez, EA
Melnick, JZ
Williams, LA
Sprague, SM
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : A38 - A38
[45] IMPROVED RESOURCE UTILIZATION OUTCOMES ASSOCIATED WITH PREDIALYSIS USE OF PARICALCITOL FOR SECONDARY HYPERPARATHYROIDISM (SHPT)
Marx, S.
Frye, C. B.
Khan, S. S.
Harshaw, Q.
Audhya, P.
Deering, K.
Sterz, R.
VALUE IN HEALTH, 2010, 13 (03) : A77 - A78
[46] BONE-HISTOLOGY IN UREMIC CHILDREN WITH SECONDARY HYPERPARATHYROIDISM
MARIE, PJ
GLORIEUX, FH
DELVIN, EE
ROBITAILLE, P
CALCIFIED TISSUE INTERNATIONAL, 1983, 35 (4-5) : 672 - 672
[47] Race is a major determinant of secondary hyperparathyroidism in uremic patients
Omije, D
Wang, JH
Ward, HJ
Pan, D
Gupta, A
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 473A - 473A
[48] Cinacalcet HCL for Treatment of Secondary Hyperparathyroidism (SHPT) in Hemodialysis Patients: A Single Centre Experience
Qaisar, Mansoor Abbas
Nadeem, Muhammad
Chattah, Fateh Sher
Roop, Zarmina
Hashir, Muhammad Mujtaba
Iqbal, Bushra
PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2019, 13 (04): : 995 - 997
[49] Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism
Tuna, Kubra
Ilkun, Olesya
Dziegielewski, Peter T.
Sharma, Anu
AACE CLINICAL CASE REPORTS, 2025, 11 (01): : 5 - 9
[50] REVERSAL OF SECONDARY HYPERPARATHYROIDISM BY CIMETIDINE IN CHRONICALLY UREMIC DOGS
JACOB, AI
CANTERBURY, JM
GAVELLAS, G
LAMBERT, PW
BOURGOIGNIE, JJ
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (06): : 1753 - 1760

← 1 2 3 4 5 →